Date: August 12, 2026

KMP / Board / Auditor Changes

Not Specified

Dividend Declaration or Non-Declaration

Not Specified

Board Meeting Outcomes

  • Board of Directors meeting held on August 12, 2026 adopted revised "Code of Conduct for Prevention of Insider Trading and Fair disclosure of Unpublished Price Sensitive Information" ("Insider Trading Code")
  • The revised code supersedes the earlier code and is effective from August 12, 2026

Financial Results

Not Specified

Disinvestment / Strategic Actions

Not Specified

Other Operational / Legal / Strategic Disclosures

Code of Fair Disclosure of Unpublished Price Sensitive Information

  • Company Secretary acts as Chief Investor Relations Officer for dissemination of information and UPSI disclosure
  • Requires prompt disclosure of UPSI that would impact price discovery
  • Mandates uniform dissemination of UPSI to avoid selective disclosure
  • Requires appropriate response to queries on news reports and market rumors
  • Information shared with analysts must not be UPSI
  • Prior intimation of analyst meets and transcripts must be published on company website
  • All UPSI handled on need-to-know basis
  • Persons receiving UPSI for legitimate purposes are considered insiders and served confidentiality notices
  • Maintains structured digital database of persons/entities with whom UPSI is shared, including PAN or other identifiers
  • Established online IT portal for pre-clearance applications and trade reporting
  • Adopted policies for inquiry in case of leak or suspected leak of UPSI

Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders

Key Definitions
  • Designated Persons include: employees designated based on role/access to UPSI, employees of material subsidiaries, all promoters, CEO and employees up to two levels below CEO, support staff with UPSI access
  • Unpublished Price Sensitive Information (UPSI) includes: financial results, dividends, change in capital structure, M&A activities, changes in key managerial personnel, rating changes, fund raising, agreements impacting management/control, fraud/defaults, resolution plans, insolvency proceedings, forensic audits, regulatory actions, litigation outcomes, guarantees, license changes
Trading Plan Provisions
  • Insiders may formulate trading plans presented to Compliance Officer for approval
  • Trading cannot commence earlier than 120 calendar days from public disclosure
  • Must set parameters: value/number of securities, nature of trade, specific date/period (≤5 consecutive trading days), price limits (±20% of previous closing price)
  • Compliance Officer must review and approve within two trading days
  • Trading window norms not applicable for trades under approved plan
  • Plan is irrevocable except due to permanent incapacity, bankruptcy, or operation of law
Trading Window and Pre-clearance
  • Trading window closed from end of every quarter until 48 hours after declaration of financial results
  • Designated Persons and immediate relatives cannot trade during closed window
  • ESOP exercise allowed during closed window, but sale of allotted shares prohibited
  • Pre-clearance required for trades ≥5,000 shares or ≥₹5 lakhs market value, whichever is lesser
  • Trades must be executed within 7 days of pre-clearance approval
  • Opposite transactions prohibited within 6 months (excluding stock option exercises)
  • Primary market subscriptions require 30-day holding period
Reporting Requirements
  • Promoters/KMPs/Directors must disclose holdings within 30 days of regulations taking effect
  • New appointees must disclose holdings within 7 days of appointment
  • Continual disclosure required for trades aggregating >₹10 lakhs value per calendar quarter within 2 trading days
  • Automated through System Driven Disclosures (SDD) mechanism
Penalties for Non-compliance
  • Monetary penalty up to 300% of profits earned from non-compliant transactions
  • Disciplinary action including wage freeze, suspension, ineligibility for ESOPs
  • Warning letters or monetary penalties for violations with negligible quantitative benefit
Institutional Mechanisms
  • CEO/MD responsible for adequate internal controls to prevent insider trading
  • Audit Committee must review compliance at least once per financial year
  • Compliance Officer authorized to conduct inquiries on UPSI leaks